Sonnet Biotherapeutics Holdings, Inc. has entered into a ChEF Purchase Agreement and a Registration Rights Agreement with Chardan Capital Markets LLC for a committed equity facility, allowing the company to sell up to $25 million of newly issued shares of common stock to Chardan at its discretion.